In vitro studies of 223Ra- and 225Ac-labelled α-zirconium phosphate as potential carrier for alpha targeted therapy

Sakmár, Michal; Ondrák, Lukáš; Fialová, Kateřina; Vlk, Martin; Kozempel, Ján; Bruchertseifer, Frank; Morgenstern, Alfred

doi:10.1007/s10967-022-08742-y

Cited by 3 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As opposed to the BFC approach, the use of nanocarriers does not strictly require a perfectly tailored chemistry (Kleynhans et al 2021). Nanoparticles based on metal salts or oxides (Gaweda 2019;Reissig et al 2019Reissig et al , 2020bRojas et al 2015;Sakmár et al 2023;Suchánková et al 2020b, a) and nanozeolites have been considered (Czerwińska et al 2020;Lankoff et al 2021;Piotrowska et al 2013Piotrowska et al , 2017. Indeed, these carriers displayed the capability to incorporate metal cations and retain both Ra radionuclides and their recoiling daughters.…”

Section: Alternative Approaches To Bind Radium Radioisotopesmentioning

confidence: 99%

The Curies’ element: state of the art and perspectives on the use of radium in nuclear medicine

Franchi,

Asti,

Di Marco

et al. 2023

EJNMMI radiopharm. chem.

View full text Add to dashboard Cite

Background The alpha-emitter radium-223 (223Ra) is presently used in nuclear medicine for the palliative treatment of bone metastases from castration-resistant prostate cancer. This application arises from its advantageous decay properties and its intrinsic ability to accumulate in regions of high bone turnover when injected as a simple chloride salt. The commercial availability of [223Ra]RaCl2 as a registered drug (Xofigo®) is a further additional asset. Main body The prospect of extending the utility of 223Ra to targeted α-therapy of non-osseous cancers has garnered significant interest. Different methods, such as the use of bifunctional chelators and nanoparticles, have been explored to incorporate 223Ra in proper carriers designed to precisely target tumor sites. Nevertheless, the search for a suitable scaffold remains an ongoing challenge, impeding the diffusion of 223Ra-based radiopharmaceuticals. Conclusion This review offers a comprehensive overview of the current role of radium radioisotopes in nuclear medicine, with a specific focus on 223Ra. It also critically examines the endeavors conducted so far to develop constructs capable of incorporating 223Ra into cancer-targeting drugs. Particular emphasis is given to the chemical aspects aimed at providing molecular scaffolds for the bifunctional chelator approach.

show abstract

Section: Alternative Approaches To Bind Radium Radioisotopesmentioning

confidence: 99%

The Curies’ element: state of the art and perspectives on the use of radium in nuclear medicine

Franchi,

Asti,

Di Marco

et al. 2023

EJNMMI radiopharm. chem.

View full text Add to dashboard Cite

show abstract

Biodistribution study of 211Pb progeny released from intravenously applied 223Ra labelled TiO2 nanoparticles in a mouse model

Sakmár,

Kozempel,

Kučka

et al. 2024

Nuclear Medicine and Biology

View full text Add to dashboard Cite

Recent Advances in Metal Oxide and Phosphate Nanomaterials Radiolabeling with Medicinal Nuclides

Janská,

Sakmár,

Štíbr

et al. 2024

ACS Omega

View full text Add to dashboard Cite

The utilization of nanomaterials in biomedical applications has surged in recent years; yet, the transition from research to practical implementation remains a great challenge. However, a promising area of research has emerged with the integration of nanomaterials with diagnostic and therapeutic radionuclides. In this Review, we elucidate the motivations behind selecting metal oxide- and phosphate-based nanomaterials in conjunction with these radionuclides, while addressing its issues and limitations. Various metal oxide- and phosphate-based nanoparticles, exhibiting low toxicity and high tolerability, have been proposed for diverse biomedical applications, ranging from bone substitutes to drug delivery systems and controlled release vectors for pharmaceuticals, including radionuclides for nuclear medicine imaging and therapy. Moreover, the potential synergistic effects of multimodal combinational therapies, integrating chemotherapeutics, immunomodulators, or hyperthermia, underscore the versatility of these nanoconstructs. Our comprehensive exploration includes the underlying principles of radiolabeling strategies, the pivotal attributes of nanomaterial platforms, and their applications. Through this perspective, we present the potential of nanotechnology-enabled nuclear medicine. Furthermore, we discuss the potential systemic and local applications of these nanoconstructs, considering their in vitro and in vivo characteristics, as well as their physicochemical properties.

show abstract

In vitro studies of 223Ra- and 225Ac-labelled α-zirconium phosphate as potential carrier for alpha targeted therapy

Cited by 3 publications

References 20 publications

The Curies’ element: state of the art and perspectives on the use of radium in nuclear medicine

The Curies’ element: state of the art and perspectives on the use of radium in nuclear medicine

Biodistribution study of 211Pb progeny released from intravenously applied 223Ra labelled TiO2 nanoparticles in a mouse model

Recent Advances in Metal Oxide and Phosphate Nanomaterials Radiolabeling with Medicinal Nuclides

Contact Info

Product

Resources

About